Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Float Percentage Of Total Shares Outstanding : N/A (As of Apr. 28, 2024)

View and export this data going back to 2005. Start your Free Trial

What is Cyclacel Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cyclacel Pharmaceuticals's float shares is 0.33 Mil. Cyclacel Pharmaceuticals's total shares outstanding is 0.00 Mil. Cyclacel Pharmaceuticals's float percentage of total shares outstanding is N/A.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cyclacel Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cyclacel Pharmaceuticals's Institutional Ownership is 0.00%.

Cyclacel Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Cyclacel Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.33	/	0.00
	=	N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (NAS:CYCCP.PFD) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

CYCC:USA UXI:Germany

Address

200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922

Website

https://www.cyclacel.com

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.